Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 367 across all filing types
Latest filing 2024-05-07 Regulatory Filings
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new marketing campaign for a product by Piramal Pharma Limited. It contains no financial data, no regulatory or compliance information, no voting results, no management or board changes, no earnings or interim report data, and no legal or merger-related content. The document is essentially a corporate communication to stock exchanges and the public about a marketing initiative. It is not a financial report or regulatory filing. Given the nature of the content, it best fits the category of a Regulatory Filing (RNS) as a general announcement that does not fit into any other specific category.
2024-05-07 English
Board Meeting — PIRAMAL PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the peri…
Regulatory Filings
2024-04-30 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a notification about an upcoming conference call scheduled for May 13, 2024, to discuss Q4 and FY2024 financial results of Piramal Pharma Limited. It includes dial-in details and registration information for investors and analysts. The document does not contain any financial data, analysis, or detailed discussion of results itself. It is an announcement of a conference call event rather than the transcript or report of the call or financial results. Therefore, it fits the category of a Call Transcript announcement or notification. However, since it is only an intimation of the conference call and not the transcript itself, the best fitting category is Regulatory Filings (RNS) as a general regulatory announcement under SEBI Listing Regulations. The document length is under 5,000 characters and it is an announcement, not the actual report or transcript.
2024-04-30 English
Board Meeting — Financial Results/Dividend
Board/Management Information Classification · 95% confidence The document is a short notice informing about an upcoming Board Meeting scheduled for May 10, 2024. It mentions that the Board will consider and approve the Audited Financial Results for the fiscal year ended March 31, 2024, and also consider recommending a dividend payment. The document is dated April 30, 2024, and is addressed to stock exchanges as per regulatory requirements. The length is only 1723 characters, which is quite short and does not contain any actual financial data or detailed results. It is an announcement of a future event (Board Meeting) and not the actual financial report or results. The document is clearly an announcement related to board/management activities, specifically a board meeting notice. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-04-30 English
Updates
Regulatory Filings Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges, referencing a regulatory requirement under SEBI Listing Regulations (Regulation 30). It informs about receipt of assessment orders related to a penalty for a pre-acquisition period. The document explicitly states it is a disclosure under Regulation 30, which pertains to material event disclosures. It does not contain financial statements, detailed financial data, or management discussion. The length is only 1757 characters, indicating it is a brief announcement rather than a full report. There is no indication of it being an earnings release, annual report, or any other detailed filing. This fits the category of a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2024-04-27 English
Updates
Regulatory Filings Classification · 100% confidence The document is a short disclosure letter addressed to stock exchanges regarding an order received from a regulatory authority (Regional Provident Fund Commissioner) about damages levied under a specific labor law. It is a regulatory announcement under SEBI Listing Regulations, specifically Regulation 30, which mandates disclosure of material events. The document does not contain financial statements, audit information, or detailed management discussion. It is not a report but a regulatory filing informing the market about a legal/regulatory event. The length is short (1713 characters), and it is clearly a regulatory announcement rather than a full report or financial document. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-04-19 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.